PALO ALTO, CALIFORNIA / ACCESS Newswire / December 17, 2025 / Bioz, Inc., the leading AI-powered platform that transforms published scientific data into actionable product insights, is pleased to ...

The Global 3D Cell Culture Market is poised for strong double-digit growth by 2027, driven by rapid advancements in biotechnology, growing interest in advanced disease models, and a rising need for ...

Generative AI in healthcare refers to advanced algorithms capable of generating new, original medical data or insights by learning patterns from existing datasets. These systems utilize deep learning ...

OverviewThe global bone void fillers (BVFs) market is poised to grow steadily at a CAGR of around 5% over the next five years, driven by the rising prevalence of orthopedic disorders, increasing ...

Dental CAD/CAM Market OverviewThe global dental CAD/CAM market is experiencing steady expansion and is projected to register a high single-digit growth rate through 2027.This growth reflects the ...

Global Research Antibodies and Reagents Market OverviewThe global research antibodies and reagents market is expected to expand at a CAGR of 7% between 2025 and 2030, driven by the rising need for ...

First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and global clinical development strategy to expedite development process —Hong Kong, Shanghai & Florham ...

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysianumares Health appoints BioD Medica for local distribution MDA filing for additional CE-marked product is currently in ...

Senzime AB (publ.) today announced that its Next-generation TetraGraph® system has received regulatory clearance for sale in Japan from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

GSK’s Exdensur is approved by the US FDA as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and ...

Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of ...

VANCOUVER, BC / ACCESS Newswire / December 17, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...